Skip to main content
PMC home page
Nature Portfolio logoLink to Nature Portfolio
. 2012 Feb 14;26(7):1564–1575. doi: 10.1038/leu.2012.13

Quantification of subclonal distributions of recurrent genomic aberrations in paired pre-treatment and relapse samples from patients with B-cell chronic lymphocytic leukemia

S J L Knight 1,2, C Yau 3, R Clifford 4, A T Timbs 4, E Sadighi Akha 2, H M Dréau 4, A Burns 1,4, C Ciria 5, D G Oscier 6, A R Pettitt 7, S Dutton 5, C C Holmes 2,3, J Taylor 1,2, J-B Cazier 2, A Schuh 1,4,*
PMCID: PMC3505832  PMID: 22258401

Abstract

Genome-wide array approaches and sequencing analyses are powerful tools for identifying genetic aberrations in cancers, including leukemias and lymphomas. However, the clinical and biological significance of such aberrations and their subclonal distribution are poorly understood. Here, we present the first genome-wide array based study of pre-treatment and relapse samples from patients with B-cell chronic lymphocytic leukemia (B-CLL) that uses the computational statistical tool OncoSNP. We show that quantification of the proportion of copy number alterations (CNAs) and copy neutral loss of heterozygosity regions (cnLOHs) in each sample is feasible. Furthermore, we (i) reveal complex changes in the subclonal architecture of paired samples at relapse compared with pre-treatment, (ii) provide evidence supporting an association between increased genomic complexity and poor clinical outcome (iii) report previously undefined, recurrent CNA/cnLOH regions that expand or newly occur at relapse and therefore might harbor candidate driver genes of relapse and/or chemotherapy resistance. Our findings are likely to impact on future therapeutic strategies aimed towards selecting effective and individually tailored targeted therapies.

Keywords: B-CLL, clonal architecture, genome-wide arrays, OncoSNP, genome imbalance, copy neutral loss of heterozygosity

Introduction

Genome-wide array approaches and sequencing analyses are powerful tools for identifying genetic aberrations in cancers, including leukemias and lymphomas.1, 2, 3, 4, 5, 6, 7, 8, 9, 10 B-cell chronic lymphocytic leukemia (B-CLL) is the most common adult leukemia in the Western World.11, 12 It is characterized by a chronic relapsing course and the development of chemotherapy refractoriness, leading to death in a significant subset of patients. There is, therefore, a clinical need to develop novel treatment strategies that overcome chemotherapy resistance.

B-CLL can be subclassified according to immunoglobulin heavy chain variable gene sequence (IGHV) homology into ‘mutated' or ‘unmutated' cases, reflecting good or poor prognosis, respectively. B-CLL shares many of the molecular characteristics seen in other forms of cancer and recurrent copy number alteration (CNAs) with relevance to prognosis have been described, including trisomy of chromosome 12 (16%) and loss of chromosomal regions 17p13.1 (TP53; 7%),13, 14, 15, 16, 17 11q22.3 (ATM; 18%)18, 19 and 13q14.3 (DLEU2 and/or miR-15a/16-1; 55%).20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 In addition, single-nucleotide polymorphism (SNP) and comparative genomic hybridization arrays have allowed novel recurrent genomic abnormalities to be identified31, 32, 33 that have been linked to prognosis in B-CLL.30, 34, 35, 36, 37, 38

Current models of cancer progression are based on the concept that tumors are subject to the Darwinian process of evolution and selection.39, 40 Recent studies in acute lymphoblastic leukemia have provided pivotal insights into the complex sequence of events during leukemogenesis, showing that the initiating mutation is followed by CNAs that drive the emergence of frank leukemia.39, 40, 41, 42 Together, these data imply that at least some CNAs/copy neutral loss of heterozygosity regions (cnLOHs) are likely to be involved in driving leukemia progression and therefore might contribute to relapse.

This led us to hypothesize that subclones containing driver CNAs/cnLOHs would newly occur or expand in relapse samples compared with samples taken before treatment and would be recurrent within our patient cohort. In contrast, random passenger mutations would remain unchanged or decrease/disappear in paired pre-treatment/relapse samples and would not be observed recurrently in different patients within the cohort. If correct, then we would anticipate that the identification of driver genes within recurrent or emerging/expanding regions of CNA/cnLOH might, in the longer term, have the potential to inform the design of novel therapies aimed at treating relapsed B-CLL.

In the present study we tested our hypothesis by systematically tracking the presence and subclonal distribution of CNAs/cnLOHs in patients before treatment and at subsequent relapse. To achieve this, we used high-resolution SNP array technology. We chose the newly developed computational statistical tool OncoSNP10 that provides quantitative measures of cell admixture on a per-SNP level. OncoSNP was selected in preference to other dedicated cancer tools for SNP array analysis,43, 44, 45, 46, 47 because our data were generated from samples at two time points only and our study was specific to B-CLL, where spatial heterogeneity (for example, samples biopsied from different parts of a tumor, metastases, etc) is not applicable (see Supplementary Information, online). Furthermore, we were interested not only in the accumulation of genomic aberrations over time, but also particularly in the expansion of distinct subclones. Thus, OncoSNP best suited our study where (i) samples differed from solid tumors in being generally diploid with comparatively fewer CNAs (ii) normal cell contamination could be minimized and (iii) we had a specific interest in subclonal evolution.

Patients and methods

For a detailed account of the Materials, Patients and Methods used in this study please refer to the Supplementary Information online.

Patients and samples

All patients gave written informed consent in accordance with the Declaration of Helsinki. In all, 135 samples from 93 patients were included in our cohort. For 42 of the 93 patients, paired pre-treatment and relapse samples were available. Only samples from patients with lymphocytes contributing >90% of the total white blood cell count were included in the analysis. DNA was extracted from vital frozen cells using the QIAamp DNA Midi Kit (Qiagen, Hilden, Germany) according to the manufacturer's protocol.

Fluorescence in situ hybridization (FISH)

Interphase cells from CLL cultures were analyzed by FISH using the Vysis CLL FISH panel probe set (Abbott Molecular, Illinois, IL, USA) according to manufacturer's instructions.

Arrays

Hybridization to Illumina Genome-wide SNP chips was performed according to manufacturer's protocols found on registration at http://www.illumina.com/products/human1m_duo_dna_analysis_beadchip_kits.ilmn and at http://www.illumina.com/support/array/array_kits/humanomni1-quad_beadchip_kit/documentation.ilmn. The data were processed using GenomeStudioV2009.2 (Illumina, Inc., San Diego, CA, USA) and then analyzed using OncoSNP v1.0 (see below). For visual comparisons, the data were processed also using Nexus 5 Discovery Edition (BioDiscovery, Inc., El Segundo, CA, USA).

OncoSNP analysis

Detailed methods have been described previously10 and further details are given in the Supplementary Information online. To help identify and exclude germline CNVs of unlikely relevance from our data, we excluded SNP and monomorphic copy number probes in known germline CNV regions from the OncoSNP analysis and we also made use of the database of genomic variants48 and the Wellcome Trust Case Control Consortium cohort data (see www.wtccc.org.uk).

TP53 mutation analysis

TP53 was screened for mutations using four high-resolution melting assays covering exons 5–8. Following high-resolution melting, results were analyzed on the high-resolution melting module of the Corbett Rotor-Gene 6000 software 1.7 (available for download from QIAGEN, http://www.qiagen.com/corbett/support/default.aspx). Positive PCR products were purified and then sequenced from both strands on the CEQ 8000 (Beckman Coulter, Fullerton, CA, USA).

IGHV mutation analysis

To identify clonal rearrangements of the IGHV gene and determine the somatic mutation status of the variable (V) gene sequence in patients we used the IGH Somatic Hypermutation Assay v2.0 (Invivoscribe, La Coutat, France) according to the manufacturer's instructions.

Results

A flowchart outlining the patient numbers and overall study design is given in Supplementary Figure 1 online.

Our preliminary experiments demonstrated the importance of selecting an array platform capable of detecting CNAs and cnLOH (see Supplementary Information, Supplementary Table 1 and Figure 2 online) as we found regions of cnLOH signposting genes that might carry mutations relevant for treatment choice and that would otherwise have been missed using a non-SNP-based platform (for example, TP53, see Supplementary Information, Supplementary Table 2 and Figure 3 online). We also demonstrated in these experiments that OncoSNP provided accurate quantification of CNAs, based on the strong correlation between OncoSNP results and conventional FISH analysis (Supplementary Table 3 and Figure 4 online).

Genome-wide analysis of pre-treatment samples

For our main study, we focused initially on the analysis of pre-treatment samples from 93 patients undergoing regular follow-up at our institutions. This cohort was representative of CLL cohorts with a higher proportion of unmutated IGHV genes and/or treatment resistant cases that are referred to tertiary centers for treatment consideration (Table 1). A total of 80 patients had one or more CNAs/cnLOHs in well-established regions of prognostic importance - 17p13.1, trisomy 12, 13q14.3, 11q22.3 (Table 1, Supplementary Table 2, Figures 2, 3 and 5 online). CNAs involving chromosome arms 8p, 9p and 10q developed exclusively in patients with unmutated IGHV.

Table 1. Characteristics of patients included in the study.

Pre-treatment analysis (n=93)
Patient Characteristics   Patient numbers
At time of blood sample:    
 Mean age (range)   66.75 (36–87) years
     
 Females   28
 Males   65
     
 del11q22.3   17
 del13q14.3   47 (28 as sole abnormality)
 Trisomy 12   14
 del17p13.1   8
 None of these   26
     
 TP53 bi-allelic mutations   3
 TP53 mono-allelic mutation   3
 TP53 mutation/del17p   8
 TP53 wt/del17p   1
 TP53 mutation negative   68
 TP53 mutation not done   10
     
 Mutated IGHV genes   25
 Unmutated IGHV genes   42
 Not known   26
     
 W and W (CRS=0)   16
 PFS>1 year (CRS=1)   22
 PFS<1 year (CRS=2)   20
 Refractory (CRS=3)   18
 FU<1 year (CRS=N/A)   15
 NK (CRS=N/A)   2
     
Treatments following blood sampling    
 Chlorambucil   16
 Chlorambucil + Rituximab or Chlorambucil + Ofatumumab   3
 Bendamustine single agent   1
 Purine analogue combination   12
 Purine analogue combination + Rituximab   11
 Ofatumumab single agent   1
 Alemtuzumab   1
 Chemotherapy refractory   18
 NK   14
     
Number of CNAs/cnLOHs    
 None   13
 <3   39
 ⩾3   41
     
Length of CNAs /cnLOHs    
 <1Mb   32
 1–5Mb   11
 >5Mb   50
     
Paired (Pre-treatment and Relapse) analysis (n=42)
Patient Characteristics
 Patient numbers
 Clonal evolution (n=25)
del11q22.3 5 4
del13q14.3 21 (13 as sole abnormality) 7
Trisomy 12 7 2
del17p13.1/TP53 mutation 5 5
None of these 12 5
     
Mutated IGHV genes 13 7a
Unmutated IGHV genes 25 14b
NK 4 4
     
PFS>1 year (CRS=1) 19 10
PFS<1 year (CRS=2) 18 10
Chemotherapy refractory (CRS=3) 5 5
Open in a new tab

Abbreviations: CNA, copy number alteration; cnLOH, copy neutral loss of heterozygosity; CRS, clinical risk score; FU, follow-up after treatment; IGVH, immunoglobulin variable heavy chain gene; NK, not known; PFS, progression free survival; W and W, Watch and Wait.

a

6/7 had % change only.

b

11/14 had newly emerging CNAs/cnLOHs.

We identified 58 previously unreported recurrent CNAs/cnLOHs (Table 2) (see Supplementary Information online for recurrence criteria). We established the minimally deleted regions (MDRs)/minimally overlapping regions (MORs) of the recurrent CNAs/cnLOHs and revealed interesting candidate genes including those implicated in B-cell maturation (for example, BLIMP1, NFkB2, TLR4, and CREBBP), tumor progression (for example, RND3, RHOT1; RHDBL; RAB20, and TRAP1), DNA damage response (for example, RIF1, TP53, ATG4D, and ATG5), tumor suppression (for example, NMI, CNOT7, PDGFRL, FGF20, PI3 K, and FOG2) and familial CLL (for example, SP140L, SP100) (Table 2). Figure 1 shows examples of four of these novel recurrent regions of interest that span only a few candidate genes, potentially facilitating the identification of driver mutations. Sequencing of the TP53 gene, the known candidate underlying poor prognosis on 17p13.1, revealed mutations in 14 out of 93 patients and deletions in 11. However, exon sequencing of two of the emergent candidates, BLIMP1 and ATG5 revealed no mutations in 40 patients.

Table 2. Newly defined regions showing recurrent/expanding CNAs/cnLOHs.

graphic file with name leu201213t1.jpg

Open in a new tab

Figure 1.

Figure 1

Open in a new tab

Four recurrent regions of interest observed in B-CLL patient samples. The boundaries of the MDRs/MORs, 2q37.1, 6q21, 9p22.3p24.1 and 10q24.32, are indicated by the vertical lines. Red lines show called losses, green lines show gains, purple lines show allelic imbalance and mustard lines show cnLOH. In each case the MDR/MOR was verified by visual inspection of Log ratio and B-allele frequency plots. P=Pre-treatment, R=Relapse.

In order to establish the clinical significance of our findings, we correlated our array results with measures of clinical prognosis and risk, including IGHV mutation status and clinical risk scores defined by necessity for treatment intervention, progression free survival and chemotherapy resistance (see Supplementary Information, online). Genomic complexity was defined either by the presence of three or more CNAs ⩾20 kb and/or cnLOHs ⩾2 Mb in addition to, or other than, the known CNA regions assayed routinely by FISH, or by a total length of CNAs ⩾5 Mb. Within the 93 pre-treatment samples, patients with unmutated IGHV genes showed a statistically significant higher total number of CNAs/cnLOHs (50.0% ⩾3 CNAs/cnLOHs) than patients with mutated IGHV genes (16.0% ⩾3 CNAs/cnLOHs) (Cochran–Armitage trend exact test, P-value=0.0032, Supplementary Table 4 online) and patients with del17p/TP53 mutation showed a higher total length of CNAs/cnLOHs (90.9% >5 Mb CNAs/cnLOHs) (Cochran–Armitage trend exact test, P-value=0.0081, Supplementary Table 5, online). In our small cohort, large Type II 13q deletions were not associated with a worse clinical outcome (Supplementary Tables 6 and 7 online).

Furthermore, patients with high clinical risk scores had a higher number of CNAs/cnLOHs than patients with low clinical risk scores (Kruskal–Wallis test, P-value=0.0016) and showed a greater overall length of CNAs/cnLOHs than patients with low clinical risk scores (Kruskal–Wallis test, P-value=0.0002) (Supplementary Table 8, online). Importantly, 16 patients had ⩾3 CNAs/cnLOH but no 17p13.1 or 11q22.3 loss and would not have been picked up by FISH as a poor risk group.

Genome-wide comparison of paired pre-treatment/relapse samples

Next, we focused on the analysis of the 42/93 patients for whom paired samples (that is, both pre-treatment and relapse samples) were available (Table 3). We hypothesized that in addition to recurrent CNAs, newly occurring or expanding genomic aberrations would also represent potential drivers of disease progression. The percentages of subclones carrying CNAs/cnLOH regions were calculated from the SNP data using OncoSNP.10 Only one case with mutated IGHV genes (CLL086) had additional CNAs at relapse. The other changes were percentage changes of pre-existing CNAs. By contrast, 11 unmutated IGHV genes cases had complex evolution with emergence of one or more additional CNAs. When we looked at total length of CNAs/cnLOHs, patients without clonal evolution showed a statistically significant lower total length of CNAs/cnLOHs (58.8%<1 Mb) than patients with clonal evolution (68.0% >5 Mb)(Cochran–Armitage trend exact test, P-value=0.0075; Supplementary Table 9, online).

Table 3. Comparison between CNA and cnLOH events noted in sequential pre-treatment versus relapse samplesa.

Patient no. Known CNAs IGHV gene status CRS CNAs and cnLOH regions in pre-treatment sample Differences at relapse
CLL010 None Unmutated 1 None noted None noted
CLL023 None Unmutated 1 46,XX, arr 4q24(107,162,437-107,237,623)x3b, 40% 10p12.23(17,833,779-18,398,113)x1, 40% 10q24.32q25.2 (103,562,915-112,637,185)x1 46,XX, arr 10p12.23(17,833,779-18,398,113)x1 no longer detectable, ∼10% 10q24.32q25.2 (103,562,915-112,637,185)x1
CLL035 Tri12 Mutated 1 47,XX, arr 3p24.3(21,592,730-22,039,016)x1b, 12(0-132,146,663)x3 None noted
CLL050 del13q14.3 Unmutated 1 46, XX, arr 6q14.1 (83,165,917-83,265,032)x1b, 7p21.1(18,576,853-18,602,061)x3b, 11q12.3(62,082,265-62,330,255)x1b, 13q14.2q14.3(48,608,987-51,326,824)x1 None noted
CLL068 del13q14.3 Mutated 1 46,XY, arr 90% 2q22.2q24.1(144,240,156-157,961,129)x1, 13q14.2q14.3(47,595,821-50,072,312)x1 46,XY, arr >90% 2q22.2q24.1(144,240,156-157,961,129)x1
CLL080 del13q14.3 Mutated 1 46,XX, arr 3q25.31(156,553,159-156,572,680)x1b, 30% 13q14.11q14.3(40,674,362-49,342,922)x1b, ∼50% 13q14.3(49,342,923-50,332,192)x1b 46,XX, arr 80% 13q14.11q14.3(40,691,755-50,580,804)x1 (extended across region)
CLL083 None Unmutated 1 46,XX, arr 4p14(39,001,471-39,049,059)x3b, 11q25(131,123,910-131,186,533)x3b, <10% 12q14.3(64,809,667-64,853,817)x1b, 12q23.1(99,175,388-99,224,488)x1b,10% 16p12.2(20,710,305-20,790,857)x3b, 17q12(34,817,937-34,948,998)x3b 46,XY, arr 11q25(131,123,910-131,186,533)x3b no longer detectable. 12q14.3(64,809,667-64,853,817)x1b no longer detectable, 12q23.1(99,175,388-99,224,488)x1b no longer detectable, 16p12.2(20,710,305-20,790,857)x3b no longer detectable, 17q12(34,817,937-34,948,998)x3b no longer detectable
CLL085 del13q14.3 Unmutated 1 46,XY, arr 10q23.1q23.31(85,670,734-89,454,971)x2 hmz, 50% 13q14.11q21.31(43,934,565-61,368,181)x1 46,XY, arr 10q23.33(95,437,455-95,462,005)x1b
CLL089 None Unmutated 1 46, XY, arr 1q21.1(144,335,130-144,614,943)x3b; 1q25.2(174,495,962-174,547,429)x3b None noted
CLL090 tri12 del13q14.3 Mutated 1 47,XX, arr 90% 7q33q34(134,397,353-139,656,577)x1, 90% 7q36 (156,694,855-156,824,049)x1b, 50% 11q12.1qter(60,468,463-134,445,626)x2 hmz, 80% 12(0-132,146,663)x3, 80% 13q14.3(49,296,907-50,580,804)x1 47,XX, arr >90% 7q33q34(134,397,353-139,656,577)x1, >90% 7q36(156,694,855-156,824,049)x1b, 90% 13q14.3(49,296,907-50,580,804)x1
CLL091 None Mutated 1 46,XY, arr 14q24.3q31.1(77,490,883-80,987,659)x2 hmzc None noted
CLL093 del13q14.3 Mutated 1 46,XY, arr 80% 6p25.3p25.2-(94,609-4,294,807)x3, 6q14.1-qter(83,755,489-170,753,209)x1, 70% 10q25.1(109,682,821-109,770,215)x3b, 13q14.2-q14.3(47,556,552-50,610,384)x1, 70% 20q13.13(47,292,495-47,500,772)x3b None noted
CLL096 del13q14.3 Mutated 1 46,XX arr 40% 13(0-114,121,252)x2 hmz, 13q14.3(49,425,974-49,522,141)x1, 13q14.3(49,522,141-50,380,713)x0 46,XX, arr 90% 13(0-114,121,252)x2 hmz. 13q14.3(49,425,974-49,522,141)x1 no longer detectable
CLL097 del13q14.3 Mutated 1 46, XY, arr >90% 13q14.11q14.3(40,332,062-51,453,289)x1 46,XY, arr 90% 13q14.11q14.3(40,332,062-51,453,289)x1
CLL098 None Unmutated 1 None noted None noted
CLL099 None Unmutated 1 46,XY, arr 70% 1q21.1(144,099,494-144,757,265)x3b None noted
CLL101 de11q22.3 del13q14.3 Unmutated 1 46,XY, arr 11q14.1qter(77,080,067-134,445,626)x1, 60-70% 13q14.2q21.32(47,781,909-64,410,990)x1b, 50% 13q21.32q33.2(64,350,990-103,707,225)x3b, 70% 22q11.21qter(17,403,754-49,582,267)x3 None noted
CLL107 de11q22.3; del13q14.3 Unmutated 1 46,XY, arr 50% 3p21.31(46,827,053-50,133,778)x1, 50% 3p21.1(52,038,099-52,553,933)x1b, >90% 11q14.3q24.3(91,864,846-127,805,084)x1, >90% 13q14.11(40,389,170-40,761,341)x1b, >90% 13q14.11(41,687,912-41,826,016)x1b, >90% 13q14.2q14.3(47,515,748-51,333,756)x1 46,XY, arr 10% 3p21.31(46,827,053-50,133,778)x1b, 10% 3p21.1(52,038,099-52,553,933)x1 b, 80-90% del11q14.3q24.3(91,864,846-127,805,084)x1, 90% 13q14.11(40,389,170-40,761,341)x1b, 90% 13q14.11(41,687,912-41,826,016)x1b, 90% del13q14.2q14.3(47,515,748-51,333,756)x1
CLL108 None Unmutated 1 46,XX, arr 3q22.3(137,678,290-137,832,637)x1b, 80% 6q14.1q22.33(81,463,977-129,051,286)x1, 90% 11q12.3qter(62,398,575-134,445,626)x2 hmz, 80% 12pterp12.2(0-20,356,457)x2 hmz, 80% 12p12.2q21.31(20,356,457-84,251,286)x3, 80% 12q21.31qter(84,251,286-132,146,663)x2 hmz 46,XX, arr 70% 6q14.1q22.33(81,463,977-129,051,286)x1, 70% 12(0-132,146,663)x2 hmz, 30% 17pterp13.1(0-8,033,419)x1, 12p12.2q21.31(20,356,457-84,251,286)x3 no longer detectable
CLL003 de11q22.3 del13q14.3 Unmutated 2 46,XY, arr 11q22.3(104,158,306-109,733,134)x1,11q23.1q23.2(110,556,535-114,089,910)x1,11q23.3(chr11:115,527,657-116,182,933)x1, 13q14.3(49,038,530-50,906,239)x1, 17q21.33q22(45,720,750-49,017,380)x2 hmzc 46,XY, arr 5q12.1(58,925,836-58,976,604)x1
CLL006 tri12 Unmutated 2 47,XY, arr 90% 4q31.1(153,631,568-153,935,927)x1, 70% 12(0-132,146,663)x3, 17p12(13,118,349-13,171,201)x3b None noted
CLL044 del13q14.3 de17p13.1 Mutated 2 46,XY, arr 46,XY, arr 2q36.2 (225,094,102-225,617,560)x1, ∼20% 9p23p21.1(11,986,163-32,324,220)x1b , 50% 9q13qter(70,223,358-139,946,600)x3, 13q14.3(49,515,641-51,327,198)x0, 17pterp11.2(0-21,430,683)x1, 19q13.12q13.2(41,320,887-43,412,844)x2 hmzc 46,XY, arr ∼30% 9p23p21.1(11,986,163-32,324,220)x1b, <20% 9q13qter(70,223,358-139,946,600)x3b
CLL056 del13q14.3 NK 2 46,XY, arr 80% 5p13.3(37,408,772-37,784,135)x3b, 80% 9pter9p11.2(0-43,254,687)x2 hmzc, 70% 13q14.12q14.2(45,377,644-45,760,335)x3, 70% 13q14.2(46,403,477-47,574,445)x3, >90% 13q14.2(47,583,917-48,099,556)x1, 90% 13q14.2q14.3(48,719,245-50,523,975)x1, 70% 13q14.3qter(50,523,975-114,121,252)x3 46,XY, arr 30% 4pterp15.1(0-35,166,759)x1b , 90% 9pter9p11.2(0-43,254,687)x2 hmzc, ∼50% Xq26.2q28 (131,629,636-154,058,617)x2b
CLL063 de11q22.3 del13q14.3 Unmutated 2 46, XX, arr 11q14.1q24.1(77,652,729-122,488,138)x1, 13q14.11(39,758,892-39,909,885)x0b, 13q14.3(49,425,974-50,389,210)x0b, 13qcenqter(19,075,593-114,142,980)x2 hmzc None noted
CLL079 None Unmutated 2 None noted 46, XX, arr 6p25.3(746,618-789,781)x3b, 6p22.3(19,723,828-19,765,153)x3b, ∼40% 6q16.3(101,257,101-101,307,223)x3b, 6q21(109,405,342-109,444,628)x1b
CLL082 del13q14.3 Mutated 2 46, XX, arr 13q13.2-21.2(33,726,200-53,619,700)x1, 13q14.3(49,461,448-50,635,061)x0 None noted
CLL084 None Unmutated 2 46,XY, arr 4q34.1(172,446,717-172,482,835)x1b 46,XY, arr <10% 6pterp22.3(0-17,028,648)x1b,<10% 10q24.31qter (102,668,100-135,374,737)x1b, <10% 11q14.1q23.2 (78,372,164-114,844,825)x1b, <10% 17pterp11.2(0-18,877165)x1b, <10% 18pterpcen (0-13,907,055)x1b, <10% 18q21.1q21.2(41,130,378-50,155,862)x1b, <10% 18q21.33q22.1 (59,798,490-62,065,418)x1b, <10% del18q22.2qter (66,972,378-76,117,153)x1b
CLL086 None Mutated 2 46,XY, arr 3p26.3p26.1(0-7,571,446)x1, >90% Xq27.1qter(139,443,330-154,582,606)x2 46,XY, arr 11q14.3 (89,597,760-89,690,254)x3b, 12q24.23(118,811,967-118,875,247)x3b, 22q12.1(26,427,496-26,490,006)x3b
CLL087 tri12 Unmutated 2 47,XY, arr 80% 12(0-132,146,663)x3, Xp11.3p11.4(41,074,455-43,983,367)x0 None noted
CLL088 del13q14.3 Mutated 2 46,XX, arr >90% 13q14.12q14.3(45,817,763-49,547,499)x1 None noted
CLL095 tri12 NK 2 47,XY, arr 80% 2q14.3qter(129,537,170-242,497,808)x2 hmz, 6q14.1q21(79,968,009-106,917,920)x1, 70% 12(0-132,146,663)x3, >90% 20q11.2qter (30,155,027-62,435,964)x2 hmzc , 22q11.23(35,010,463-35,020,688)x0b 46,XY, arr 2p14(chr2:67,974,461-68,005,924)x3b
CLL102 tri12 Unmutated 2 47,XY, arr 80% 12(0-132,146,663)x3 None noted
CLL103 tri12 Unmutated 2 47,XX, arr 1q25.3(183,360,633-183,397,169)x3b, >90% 2q22.1q31.1(141,094,077-171,777,386)x2 hmz, >90% 9p24.1p22.3(9,000,336-14,313,346)x2 hmz, 10q26.3(135,089,371-135,374,737)x3b, 80% 12(0-132,146,663)x3, >90% 13q33.3q34(108,839,643-112,014,298)x2 hmz, 70% 22q11.21q12(17,295,655-19,791,274)x3 None noted
CLL106 del17p13.1 Unmutated 2 46,XY, arr 90% 1p34.2(41,538,823-42,112,410)x1, 90% 6p25.3p25.1(1,376,135-6,173,214)x1, 90% 6p25.1p24.3(6,471,929-7,578,657)x1, 90% 6p24.3p24.1(10,155,458-11,223,334)x1, 90% 6p24.1p22.3(12,754,522-18,670,995)x1, 90% 6p21.2(38,889,727-39,544,026)x1, 90% 6p21.1p12.3(43,689,563-46,299,596)x1,90% 7p15.3(23,346,710-24,400,934)x1, 90% 9q33.3 (127,381,099-127,900,525)x1, 90% 12p13.33(977,044-1,959,491)x1, 17pterpcen(0-22,125,162)x1, 18pterp11.31(0-6,572,104)x1, 18p11.31p11.23(6,802,509-7,333,763)x3, 18p11.22p11.21(8,926,107-13,281,880)x1, 18p11.21(13,536,937-15,348,275)x1, 90% 22q11.21(16,712,510-17,055,914)x1b, 90% 22q11.23q12.1(23,409,925-27,331,789)x1, 90% 22q12.1q12.2(27,573,410-27,918,140)x1b 46,XY, arr 80% 1p34.2(41,538,823-42,112,410)x1 , 60% 3p26.3p26.1(0-8,686,575)x1, 70% 3p25.1p22.3(12,214,891-34,481,950)x1, 70% 3p21.33p21.31(43,708,188-46,679,233)x1, 70% 3p21.1p14.2(52,515,813-61,534,811)x1, 70% 3p14.1p13(68,801,809-74,909,820)x1, 60% 8pterq11.21(0-49,228,092)x1, 60% 8q12.1q13.2(57,011,940-70,263,279)x1, 60% 8q23.1(106,323,747-106,959,523)x1, 90% 17pterpcen(0-22,125,162)x1, 90% 18pter18p11.31(0-6,572,104)x1, 90% 18p11.31p11.23(6,802,509-7,333,763)x3, 90% 18p11.22p11.21(8,926,107-13,281,880)x1, 90% 18p11.21(13,536,937-15,348,275)x1, 80% 22q11.21(16,712,510-17,055,914)x1b, 80% 22q11.23q12.1(23,409,925-27,331,789)x1, 80% 22q12.1q12.2(27,573,410-27,918,140)x1b
CLL145 de17p13.1 Unmutated 2 46,XY, arr <10% 3p25.1p14.3(12,516,876- 55.709725)x1b , <10% 5q14.3q23.3(87,285,075-129,855,075)x1b , >90% 6p24.3p22.3(10,220,342-16,992,531)x2 hmzb, 6q16.3(100,876,399-101,445,547)x1, 80% 8q22.3q24.21(106.058,337-128,286,818)x2 hmz, 80% 8q24.21(128,286,819-128,297,901)x3b, 80% 8q24.21-q24.3(128,297,902-147,274,826)x2 hmzb, 12q14.1q14.2(56,925,673-62,754,801)x2 hmzb, 16q22.3q23.1(72,290,299-76,525,557)x2 hmzb, <10%-50% 17p13.3p11.2(0-18,485,225)x2 hmzb, ∼30% 18q11q23(22,045,087-76,115,172)x2 hmzb, 80% 22q11.23(,23,991,557-24,250,622)x1b 10-20% 3p25.1p14.3(12,516,876- 55.709725)x1b , 10-20% 5q14.3q23.3(87,285,075-129,855,075)x1b , 50% 8q22.3q24.21(106.058,337-128,286,818)x2 hmz, 50% 8q24.21(128,286,819-128,297,901)x3b, 50% 8q24.21-q24.3(128,297,902-147,274,826)x2 hmzb, <10%-40% 17p13.3p11.2(0-18,485,225)x2 hmzb, ∼20% 18q11q23(22,045,087-76,115,172)x2 hmzc,
CLL156 None NK 2 46,XY, arr 80% 5q23.3 (124,282,026-124,531,381)x3b, ∼10% 19q13.12q13.13(41,440,201-43,149,438)x1 hmzb None noted
ARR003 del13q14.3 Unmutated 2 46,XY, 13q14.2q14.3(49,983,042-51,331,787)x1b 46,XY, arr 50% 11q13.1q25(66,992,701-134,177,292)x2 hmzb, 90% 13q14.2q14.3(49,970,598-51,333,659)x1b,
CLL071 del13q14.3 Mutated 3 46,XY, arr <10% 13q13.3q34(36,483,665-114,123,125)x1b, 70% 13q14.2q14.3(48,713,406-50,479,598)x1b, 13q14.3(49,229,284-50,423,376)x0, 30-70% 17pterp11.2(0-21,100,678)x2 hmz 46,XY, ∼20% 13q13.3q14.2(36,446,865-114,123,122)x1b.
CLL081 del13q14.3 de17p13.1 Unmutated 3 46,XY, arr <10% 2pterp14(0-67,981,586)x3b, 90% 2q11.1q11.2(95,597,687-97,676,314)x1, 90% 2q14.2q14.3(121,572,920-126,531,524)x1, 90% 2q14.3(127,036,406-128,569,251)x1, 90% 2q21.2q24.1(134,752,138-155,542,922)x1, 40% 8q22.2qter(100,925,155-146,263,890)x3, 90% 9pterp11.2(0-33,318,812)x1, 90% 9p13.3p11.2(33,831,777-43,548,708)x1, >90% 9q21.13(74,372,294-74,516,002)x1b, <10% 10q23.2q23.31(89,306,467-93,720,035)x1b, 90% 11q12.2q13.1(61,231,809-64,790,450)x1, 70% 12q13.11q13.12(47,308,669-48,029,106)x3, 50% 13q11q13.1(17,920,393-32,659,455)x1, 50% 13q14.3(48,898,975-50,805,219)x1, 90% 17pterpcen(0-22,125,162)x1, 70% 17qcenqter(22,713,949-78,637,198)x3; 90% 19pterp13.2(0-10,071,486)x1; 70% 19p13.2p13.13(10,071,486-13,419,854)x3 46,XY, arr ∼50% 2pterp14(0-67,981,586)x3b, >90% 2q11.1q11.2(95,597,687-97,676,314)x1, >90% 2q14.2q14.3(121,572,920-126,531,524)x1, >90% 2q14.3(127,036,406-128,569,251)x1, >90% 2q21.2q24.1(134,752,138-155,542,922)x1, ∼10% 2q31.1(174,294,144-174,955,141)x1b, ∼30% 2q33.1q37.1(204,070,804-231,244,281)x1b, 90% 8q22.2qter(100,925,155-146,263,890)x3, >90% 9pterp11.2(0-33,318,812)x1, >90% 9p13.3p11.2(33,831,777-43,548,708)x1, 40% 10q23.2q23.31(87,419,694-107,982,339)x1, >90% 11q12.2q13.1(61,231,809-64,790,450)x1,∼10% 13q11q13.1(17,920,393-32,659,455)x1, <10% 13q14.3(48,898,975-50,805,219)x1b, ∼30% 16p13.3(3,407,330-4,492,425)x1b , >90% 17pterpcen(0-22,125,162)x1, >90%19pterp13.2(0-10,071,486)x1
CLL092 de11q22.3 del13q14.3 Unmutated 3 46,XY, arr 2p16.1(55,330,268-55,352,382)x1b, 11q22.3q24.3(103,008,248-127,852,266)x1, 13q14.3(49,500,283-50,255,794)x1, ∼20% 20q11.22qter(32,772,470-62,385,675)x2 hmzc 46,XY, ∼10% 11q22.1(101,354,200-101,514,796)x1b, arr 40% 20q11.22qter(32,772,470-62,385,675)x2 hmz
CLL094 de17p13.1 Unmutated 3 46,XY, arr 30% 2q33.2q36.3(206,690,791-230,780,953)x1, 40% 17pterp11.2(0-20,067,160)x1b, 60% 17p11.2(20,067,161-21,471,049)x1b 46,XY, arr 20% 2pterp21(0-45,928,191)x1, 20% del2p16.32p16.1(48,617,246-59,276,760)x1, 20% 2p13.2p11.2(73,382,585-83,989,328)x1b, 2q33.2q36.3(206,690,791-230,780,953)x1 (no longer detectable); 20% 6p24.3p25.2(3,138,439-9,391,113)x1, 20% 6p22.3(16,521,154-19,237,784)x1, 20% 6p21.31(35,154,526-36,820,525)x1b, 20% 6p21.2(37,804,382-38,908,035)x1b, 20% 6p21.1q12(48,685,550-67,685,569)x1b, 20% 6q13q15(74,279,874-88,065,764)x1, 20% 6q21q22.1(111,800,880-116,278,896)x1b, 20% 6q22.33(127,739,685-130,160,593)x1, 20% 7q21.11(80,379,709-85,591,711)x1, 20% 7q31.1q32.1(111,820,986-127,193,285)x1, 20% 7q32.3qter(130,945,628-157,796,605)x1, 20% 8pterp12(0-36,598,375)x1b, 20% 10q24.1qter(98,893,384-135,085,880)x1, 50% 11q13.1q25 intermittent(63,515141-131,026,292)x3b, 70% 17q11.2(24,979,666-25,506,441)x1, 70% 17q11.2(27,442,088-27,692,902)x1b, 60% 19p13.3p13.11(5,676,493-18,095,588)x3, 70% 19p13.11p12(18,201,910-24,337,497)x1
CLL112 del13q14.3 NK 3 46,XYarr 90% 2q35(218,476,667-220,204,673)x1, 90% 2q36.3q37.1(230,239,060-231,446,513)x1, 8q21.11q21.13(78,181,345-80,471,188)x2 hmzc ,>90% 13q11.2qter(20,381,113-113,908,097)x2 hmz, 13q14.3(49,494,577-50,238,316)x0, 80% 16p12.1(21,860,290-22,350,261)x1 46,XYarr 90% 2q35(218,476,667-220,204,673)x1 no longer detectable, 90% 2q36.3q37.1(230,239,060-231,446,513)x1 no longer detectable, >90% 13q11.2qter(20,381,113-113,908,097)x2 hmz no longer detectable, 13q14.3(49,494,577-50,238,316)x0 no longer detectable
Open in a new tab

Abbreviations: CNA, copy number alteration; cnLOH, copy neutral loss of heterozygosity; CRS, clinical risk score; hmz, homozygous; IGVH, immunoglobulin variable heavy chain gene; NK, not known.

All co-ordinates are hg36 and determined using OncoSNP except ‘c' (see above).

‘x2 hmz' indicates cnLOH.

a

Using size thresholds of 20 kb for CNAs (unless in a known region of interest) and 2 Mb for cnLOH. Percentages represent levels of mosaicism estimated from B-allele frequency values. Where a percentage is not noted, then all cells appear to carry the anomaly.

b

Co-ordinates determined using Nexus (because of variable CNA boundaries less well defined by OncoSNP or <500 kb in size or below the level of detection of OncoSNP).

c

Called by OncoSNP as possible germline variant and manually verified as probable somatic event. Co-ordinates determined using Nexus.

All 13q14.3 deletions were present before treatment and of the 21 patients manifesting these; seven exhibited ⩾10% changed proportions of subclones carrying the deletion at relapse. In two cases, (CLL081 and CLL107), the proportion of subclones with the del13q14.3 appeared decreased at relapse and both exhibited additional CNAs elsewhere in the genome. For another two cases (CLL080 and CLL096), with deletions >1 Mb, the proportion of subclones with the 13q14.3 deletion had increased over time; both had isolated chromosome 13 anomalies (Figure 2). Furthermore, in CLL071 and CLL080, there was extension of the 13q13.4 deletion in one allele (Supplementary Figure 6 online, Supplementary Table 5). Overall, the results suggest that extension of the deleted 13q14.3 locus may confer a clonal survival advantage in the minority of cases without additional CNAs/cnLOHs. By contrast, for patients with complex genomic aberrations, clones containing del13q14.3 are outcompeted.

Figure 2.

Figure 2

Open in a new tab

OncoSNP output showing clonal expansion events involving the chromosome 13q14.3 MDR and percentages of cells involved in pre-treatment and relapse samples from CLL080 and CLL096. The red lines indicate deletion events, whereas the magenta lines indicate allelic imbalance/cnLOH. In CLL080, 30% cells carry a large 13q14.11q14.3 deletion and an additional ∼20% cells carry the smaller MDR deletion at pre-treatment. At relapse, ∼90% cells carry the larger deletion. For CLL096, there is a homozygous deletion of 13q14.3, and cnLOH of the entire chromosome in ∼40% cells at pre-treatment. This cnLOH expands to ∼90% cells at relapse.

Patients with del17p13.1/TP53 mutations were most likely to acquire additional CNAs at relapse (5/5). In addition, three patients without del17p13.1 at diagnosis developed del17p and other CNAs at relapse (CLL084 and CLL108, CLL145). Patient CLL081 was a clear example of this, manifesting a 17p13.1 deletion and multiple other CNAs pre-treatment. At the time of relapse, five CNAs had altered in proportion (Figure 3) and two events (del2q33.1-q37.1 and del16p13) were newly identified. Furthermore, a number of the CNAs identified encompassed newly identified MDRs/MORs (Table 1) and included the genes LDB-1 and NFkB2 (10q24.32 MDR), SP140L and SP100 (2q37.1 MOR) and BTBD12, DNASE1, TRAP1 and CREBBP (16p13.3 MDR). Finally, the OncoSNP feature of defining proportions of subclones carrying CNAs/cnLOHs allowed us to use data from matched pre-treatment and relapse samples to infer likely subclonal populations and to map their evolutionary relationships. Schematic representations of the likely clonal architecture at different time-points for patients CLL081 and CLL106 are shown in Figure 4 with a further example for CLL092 in Supplementary Figure 7 online. These illustrate clearly a non-linear, branching subclonal hierarchy in B-CLL with multiple ancestral subclones, already present in pre-treatment samples and contributing to relapse. In conclusion, using the combination of high-resolution SNP array and OncoSNP, we were able to detect clonal evolution in 60% of treated patients with B-CLL.

Figure 3.

Figure 3

Open in a new tab

OncoSNP output showing clonal evolution in pre-treatment and relapse samples from CLL081. This patient shows a reduction in the percentage of cells carrying the 13q abnormalities whilst other CNAs expanded (8q22.2qter and 10q23.2q23.3) or were newly identified at relapse (2q33.1q37.1 and 16p13.3).

Figure 4.

Figure 4

Open in a new tab

Schematic representation of the possible clonal architecture pre-treatment and at relapse (pale blue and mid-blue shaded areas, respectively) for patients (a) CLL106 and (b) CLL081. Proportions below 10% and above 90% and cell populations without identifiable CNAs/cnLOHs are inferred. The precision of the percentage contribution of subclones with CNAs/cnLOH is ±10%. Note that for CLL081, the proportion of subclones with the 13q14.3 loss decreases at relapse and the 12q13.11q13.12 and 19p13.13p13.2 gains are no longer observed in one subclone.

Interestingly, when comparing the regions affected by clonal expansion with recurrent regions we noticed a considerable overlap (Table 3). Many regions that were both recurrent and expanded or newly occurred in relapse samples included a very limited number of genes (Table 2, blue shading). These regions include genes that have a role in familial CLL (SP140L, SP100), in B-cell development and autophagy (BLIMP1 and ATG5, respectively) and FOG2, a regulator of phosphatidylinositol 3-kinase, which is involved in cancer proliferation and survival. A fourth region affects NFIB involved in the NFKB pathway and two genes of no obvious CLL related annotation (TYRP1, MPDZ). A further region included DNA repair genes (BTBD12, DNASE1), TRAP1, a mitochondrial chaperone and regulator of apoptosis, as well as CREBBP, a frequently mutated gene in B-cell lymphomas.

When we performed pathway analysis of the 546 genes in the MDRs/MORs affected by recurrent and emerging/expanding CNAs, we identified 17 over-represented, statistically significant and independent pathways of which eight contained 55 cancer-related genes (phagosome P-value=0.0024; apoptosis P-value=0.0079; small-cell lung cancer P-value=0.0232; prostate cancer P-value= 0.0284; pancreatic cancer P-value=0.0355; chronic myeloid leukemia P-value=0.0414; wnt signaling P-value=0.0436; cell cycle P-value=0.0497) (see Supplementary Table 10, online).

Discussion

Our study is the first genome-wide array based analysis of CNAs/cnLOHs that both characterizes and quantifies the proportion of subclones carrying genomic changes before treatment and at subsequent relapse in cancer. The results demonstrate that (i) many CNAs/cnLOHs in CLL are recurrent and therefore non-random events that expand over time owing to Darwinian selective pressure, (ii) selected genes identified in both well-recognized and newly defined MDRs/MORs present plausible candidates for driving disease progression and include those involved in mature B-cell development, DNA damage response (DNA repair, apoptosis and autophagy), tumor progression and familial B-CLL; pathway analysis was consistent with this. The identification of genes in this way will be informative for focused sequencing strategies. (iii) In our cohort there is strong supportive evidence that genomic complexity is associated with poor risk disease. This adds strength to previous studies that indicated a link between genomic complexity or clonal evolution to survival in CLL.30, 36, 38 (iv) OncoSNP is a powerful computational statistical tool that alters fundamentally our ability to investigate clonal architectures and tease apart complex clonal dynamics. Furthermore, our results demonstrate the importance of developing comparable algorithms for application to next generation sequencing data. Although it is likely that in the longer term array technology will be replaced by whole genome sequencing, this study contributes to our understanding of the significance of CNAs/cnLOH in cancer progression. Finally, our results do not support the existence of a single leukemia propagating cell population but instead, shed light on the considerable genomic heterogeneity of cells driving disease progression.

Clinically, the existence of multiple, genetically distinct, subpopulations that escape therapeutic intervention presents formidable challenges for the development of effective treatments for patients with relapsed refractory B-CLL. Therefore, detailed characterization of the molecular basis of the condition and elucidation of the underlying mechanisms of clonal diversity will be essential for future targeted selection of effective therapeutic agents.

Acknowledgments

This work was supported by the NIHR Biomedical Research Centre, Oxford with funding from the Department of Health's NIHR Biomedical Research Centres funding scheme. In addition, the publication presents independent research commissioned by the Health Innovation Challenge Fund (HICF-1009-026), a parallel funding partnership between the Wellcome Trust and the Department of Health. The views expressed in this publication are those of the authors and not necessarily those of the Wellcome Trust or the Department of Health. This study makes use of data generated by the Wellcome Trust Case–Control Consortium. A full list of the investigators who contributed to the generation of the data is available from www.wtccc.org.uk. The project was also supported by the Wellcome Trust (090532/Z/09/Z), (076113), (085475) and by Illumina, Inc. CY is funded by a UK Medical Research Council Specialist Training Fellowship in Biomedical Informatics (Ref No. G0701810). We would also like to acknowledge Dr David Bentley (Illumina Inc) and Prof Ian Tomlinson (WTCHG) for their role in supporting this work.

Author contributions

SK designed and performed the research, analyzed the data and wrote the manuscript; RC, ATT, HMD, AB and ESA helped design the research and performed experiments; ARP and DGO provided samples; CY, CCH, JB, CC and SD analyzed data and contributed to the manuscript, JT was responsible for project management and co-ordination and helped write the manuscript, AS provided samples, designed the research, analyzed the data, and wrote and edited the manuscript.

We would like to declare that OncoSNP is freely available for use in academic or non-profit research activities upon request. Isis Innovation Ltd may request a fee for the use of the software in commercial or other profit generating activities. It is the policy of Isis Innovation Ltd that a share of the revenue generated from such licensing arrangements would be distributed via the University of Oxford to CY and CCH.

Footnotes

Supplementary Information accompanies the paper on the Leukemia website (http://www.nature.com/leu)

Supplementary Material

Supplementary Information
Click here for additional data file. (1.1MB, pdf)

References

  1. Lindblad-Toh K, Tanenbaum DM, Daly MJ, Winchester E, Lui WO, Villapakkam A, et al. Loss-of-heterozygosity analysis of small-cell lung carcinomas using single-nucleotide polymorphism arrays. Nat Biotechnol. 2000;18:1001–1005. doi: 10.1038/79269. [DOI] [PubMed] [Google Scholar]
  2. Campbell PJ, Stephens PJ, Pleasance ED, O'Meara S, Li H, Santarius T, et al. Identification of somatically acquired rearrangements in cancer using genome-wide massively parallel paired-end sequencing. Nat Genet. 2008;40:722–729. doi: 10.1038/ng.128. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Stratton MR, Campbell PJ, Futreal PA. The cancer genome. Nature. 2009;458:719–724. doi: 10.1038/nature07943. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Mullighan CG, Phillips LA, Su X, Ma J, Miller CB, Shurtleff SA, et al. Genomic analysis of the clonal origins of relapsed acute lymphoblastic leukemia. Science. 2008;322:1377–1380. doi: 10.1126/science.1164266. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Beroukhim R, Mermel CH, Porter D, Wei G, Raychaudhuri S, Donovan J, et al. The landscape of somatic copy-number alteration across human cancers. Nature. 2010;463:899–905. doi: 10.1038/nature08822. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Morin RD, Mendez-Lago M, Mungall AJ, Goya R, Mungall KL, Corbett RD, et al. Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. Nature. 2011;476:298–303. doi: 10.1038/nature10351. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Puente XS, Pinyol M, Quesada V, Conde L, Ordonez GR, Villamor N, et al. Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature. 2011;475:101–105. doi: 10.1038/nature10113. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Mullighan CG, Zhang J, Kasper LH, Lerach S, Payne-Turner D, Phillips LA, et al. CREBBP mutations in relapsed acute lymphoblastic leukaemia. Nature. 2011;471:235–239. doi: 10.1038/nature09727. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Pasqualucci L, Dominguez-Sola D, Chiarenza A, Fabbri G, Grunn A, Trifonov V, et al. Inactivating mutations of acetyltransferase genes in B-cell lymphoma. Nature. 2011;471:189–195. doi: 10.1038/nature09730. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Yau C, Mouradov D, Jorissen RN, Colella S, Mirza G, Steers G, et al. A statistical approach for detecting genomic aberrations in heterogeneous tumor samples from single nucleotide polymorphism genotyping data. Genome Biol. 2010;11:R92. doi: 10.1186/gb-2010-11-9-r92. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Howlader N, Noone AM, Krapcho M, Neyman N, Aminou R, Waldron W, Altekruse SF, Kosary CL, Ruhl J, Tatalovich Z, Cho H, Mariotto A, Eisner MP, Lewis DR, Chen HS, Feuer EJ, Cronin KA, Edwards BK.edsSEER Cancer Statistics Review National Cancer Institute; Bethesda, MD, 1975–2008. . http://seer.cancer.gov/csr/1975_2008/ , based on November 2010 SEER data submission, posted to the SEER web site, 2011 [Google Scholar]
  12. CRUK . http://info.cancerresearchuk.org/cancerstats/types/leukaemia/ .
  13. Gaidano G, Ballerini P, Gong JZ, Inghirami G, Neri A, Newcomb EW, et al. p53 mutations in human lymphoid malignancies: association with Burkitt lymphoma and chronic lymphocytic leukemia. Proc Natl Acad Sci USA. 1991;88:5413–5417. doi: 10.1073/pnas.88.12.5413. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Zenz T, Mohr J, Edelmann J, Sarno A, Hoth P, Heuberger M, et al. Treatment resistance in chronic lymphocytic leukemia: the role of the p53 pathway. Leuk Lymphoma. 2009;50:510–513. doi: 10.1080/10428190902763533. [DOI] [PubMed] [Google Scholar]
  15. Stilgenbauer S, Sander S, Bullinger L, Benner A, Leupolt E, Winkler D, et al. Clonal evolution in chronic lymphocytic leukemia: acquisition of high-risk genomic aberrations associated with unmutated VH, resistance to therapy, and short survival. Haematologica. 2007;92:1242–1245. doi: 10.3324/haematol.10720. [DOI] [PubMed] [Google Scholar]
  16. Zenz T, Krober A, Scherer K, Habe S, Buhler A, Benner A, et al. Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: results from a detailed genetic characterization with long-term follow-up. Blood. 2008;112:3322–3329. doi: 10.1182/blood-2008-04-154070. [DOI] [PubMed] [Google Scholar]
  17. Malcikova J, Smardova J, Rocnova L, Tichy B, Kuglik P, Vranova V, et al. Monoallelic and biallelic inactivation of TP53 gene in chronic lymphocytic leukemia: selection, impact on survival, and response to DNA damage. Blood. 2009;114:5307–5314. doi: 10.1182/blood-2009-07-234708. [DOI] [PubMed] [Google Scholar]
  18. Stankovic T, Stewart GS, Fegan C, Biggs P, Last J, Byrd PJ, et al. Ataxia telangiectasia mutated-deficient B-cell chronic lymphocytic leukemia occurs in pregerminal center cells and results in defective damage response and unrepaired chromosome damage. Blood. 2002;99:300–309. doi: 10.1182/blood.v99.1.300. [DOI] [PubMed] [Google Scholar]
  19. Hallek M. First-line treatment with fludarabine (F), cyclophosphamide (C), and rituximab (R) (FCR) improves overall survival (OS) in previously untreated patients (pts) with advanced chronic lymphocytic leukemia (CLL): results of a randomized phase III trial on behalf of an international group of investigators and the German CLL study group. Blood (ASH Ann Meet Abstr) 2009;114:535. [Google Scholar]
  20. Dohner H, Stilgenbauer S, Benner A, Leupolt E, Krober A, Bullinger L, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med. 2000;343:1910–1916. doi: 10.1056/NEJM200012283432602. [DOI] [PubMed] [Google Scholar]
  21. Calin GA, Ferracin M, Cimmino A, Di Leva G, Shimizu M, Wojcik SE, et al. A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N Engl J Med. 2005;353:1793–1801. doi: 10.1056/NEJMoa050995. [DOI] [PubMed] [Google Scholar]
  22. Bandi N, Zbinden S, Gugger M, Arnold M, Kocher V, Hasan L, et al. miR-15a and miR-16 are implicated in cell cycle regulation in a Rb-dependent manner and are frequently deleted or down-regulated in non-small cell lung cancer. Cancer Res. 2009;69:5553–5559. doi: 10.1158/0008-5472.CAN-08-4277. [DOI] [PubMed] [Google Scholar]
  23. Cimmino A, Calin GA, Fabbri M, Iorio MV, Ferracin M, Shimizu M, et al. miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci USA. 2005;102:13944–13949. doi: 10.1073/pnas.0506654102. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Linsley PS, Schelter J, Burchard J, Kibukawa M, Martin MM, Bartz SR, et al. Transcripts targeted by the microRNA-16 family cooperatively regulate cell cycle progression. Mol Cell Biol. 2007;27:2240–2252. doi: 10.1128/MCB.02005-06. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Raveche ES, Salerno E, Scaglione BJ, Manohar V, Abbasi F, Lin YC, et al. Abnormal microRNA-16 locus with synteny to human 13q14 linked to CLL in NZB mice. Blood. 2007;109:5079–5086. doi: 10.1182/blood-2007-02-071225. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Bonci D, Coppola V, Musumeci M, Addario A, Giuffrida R, Memeo L, et al. The miR-15a-miR-16-1 cluster controls prostate cancer by targeting multiple oncogenic activities. Nat Med. 2008;14:1271–1277. doi: 10.1038/nm.1880. [DOI] [PubMed] [Google Scholar]
  27. Klein U, Lia M, Crespo M, Siegel R, Shen Q, Mo T, et al. The DLEU2/miR-15a/16-1 cluster controls B cell proliferation and its deletion leads to chronic lymphocytic leukemia. Cancer Cell. 2010;17:28–40. doi: 10.1016/j.ccr.2009.11.019. [DOI] [PubMed] [Google Scholar]
  28. Ouillette P, Erba H, Kujawski L, Kaminski M, Shedden K, Malek SN. Integrated genomic profiling of chronic lymphocytic leukemia identifies subtypes of deletion 13q14. Cancer Res. 2008;68:1012–1021. doi: 10.1158/0008-5472.CAN-07-3105. [DOI] [PubMed] [Google Scholar]
  29. Parker H, Rose-Zerilli MJ, Parker A, Chaplin T, Wade R, Gardiner A, et al. 13q deletion anatomy and disease progression in patients with chronic lymphocytic leukemia. Leukemia. 2011;25:489–497. doi: 10.1038/leu.2010.288. [DOI] [PubMed] [Google Scholar]
  30. Ouillette P, Collins R, Shakhan S, Li J, Li C, Shedden K, et al. The prognostic significance of various 13q14 deletions in chronic lymphocytic leukemia. Clin Cancer Res. 2011;17:6778–6790. doi: 10.1158/1078-0432.CCR-11-0785. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Sellick GS, Wade R, Richards S, Oscier DG, Catovsky D, Houlston RS. Scan of 977 nonsynonymous SNPs in CLL4 trial patients for the identification of genetic variants influencing prognosis. Blood. 2008;111:1625–1633. doi: 10.1182/blood-2007-08-110130. [DOI] [PubMed] [Google Scholar]
  32. Pfeifer D, Pantic M, Skatulla I, Rawluk J, Kreutz C, Martens UM, et al. Genome-wide analysis of DNA copy number changes and LOH in CLL using high-density SNP arrays. Blood. 2007;109:1202–1210. doi: 10.1182/blood-2006-07-034256. [DOI] [PubMed] [Google Scholar]
  33. Gunn SR, Mohammed MS, Gorre ME, Cotter PD, Kim J, Bahler DW, et al. Whole-genome scanning by array comparative genomic hybridization as a clinical tool for risk assessment in chronic lymphocytic leukemia. J Mol Diagn. 2008;10:442–451. doi: 10.2353/jmoldx.2008.080033. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Kujawski L, Ouillette P, Erba H, Saddler C, Jakubowiak A, Kaminski M, et al. Genomic complexity identifies patients with aggressive chronic lymphocytic leukemia. Blood. 2008;112:1993–2003. doi: 10.1182/blood-2007-07-099432. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Kay NE, Eckel-Passow JE, Braggio E, Vanwier S, Shanafelt TD, Van Dyke DL, et al. Progressive but previously untreated CLL patients with greater array CGH complexity exhibit a less durable response to chemoimmunotherapy. Cancer Genet Cytogenet. 2010;203:161–168. doi: 10.1016/j.cancergencyto.2010.09.003. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Gunnarsson R, Isaksson A, Mansouri M, Goransson H, Jansson M, Cahill N, et al. Large but not small copy-number alterations correlate to high-risk genomic aberrations and survival in chronic lymphocytic leukemia: a high-resolution genomic screening of newly diagnosed patients. Leukemia. 2010;24:211–215. doi: 10.1038/leu.2009.187. [DOI] [PubMed] [Google Scholar]
  37. Gunnarsson R, Mansouri L, Isaksson A, Goransson H, Cahill N, Jansson M, et al. Array-based genomic screening at diagnosis and follow-up in chronic lymphocytic leukemia. Haematologica. 2011;96:1161–1169. doi: 10.3324/haematol.2010.039768. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Ouillette P, Collins R, Shakhan S, Li J, Peres E, Kujawski L, et al. Acquired genomic copy number aberrations and survival in chronic lymphocytic leukemia. Blood. 2011;118:3051–3061. doi: 10.1182/blood-2010-12-327858. [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Hong D, Gupta R, Ancliff P, Atzberger A, Brown J, Soneji S, et al. Initiating and cancer-propagating cells in TEL-AML1-associated childhood leukemia. Science. 2008;319:336–339. doi: 10.1126/science.1150648. [DOI] [PubMed] [Google Scholar]
  40. Bateman CM, Colman SM, Chaplin T, Young BD, Eden TO, Bhakta M, et al. Acquisition of genome-wide copy number alterations in monozygotic twins with acute lymphoblastic leukemia. Blood. 2010;115:3553–3558. doi: 10.1182/blood-2009-10-251413. [DOI] [PubMed] [Google Scholar]
  41. Notta F, Mullighan CG, Wang JC, Poeppl A, Doulatov S, Phillips LA, et al. Evolution of human BCR-ABL1 lymphoblastic leukaemia-initiating cells. Nature. 2011;469:362–367. doi: 10.1038/nature09733. [DOI] [PubMed] [Google Scholar]
  42. Anderson K, Lutz C, van Delft FW, Bateman CM, Guo Y, Colman SM, et al. Genetic variegation of clonal architecture and propagating cells in leukaemia. Nature. 2011;469:356–361. doi: 10.1038/nature09650. [DOI] [PubMed] [Google Scholar]
  43. Sun W, Wright FA, Tang Z, Nordgard SH, Van Loo P, Yu T, et al. Integrated study of copy number states and genotype calls using high-density SNP arrays. Nucleic Acids Res. 2009;37:5365–5377. doi: 10.1093/nar/gkp493. [DOI] [PMC free article] [PubMed] [Google Scholar]
  44. Greenman CD, Bignell G, Butler A, Edkins S, Hinton J, Beare D, et al. PICNIC: an algorithm to predict absolute allelic copy number variation with microarray cancer data. Biostatistics. 2010;11:164–175. doi: 10.1093/biostatistics/kxp045. [DOI] [PMC free article] [PubMed] [Google Scholar]
  45. Van Loo P, Nordgard SH, Lingjærde OC, Russnes HG, Rye IH, Sun W, et al. Allele-specific copy number analysis of tumors. Proc Natl Acad Sci USA. 2010;107:16910–16915. doi: 10.1073/pnas.1009843107. [DOI] [PMC free article] [PubMed] [Google Scholar]
  46. Navin N, Krasnitz A, Rodgers L, Cook K, Meth J, Kendall J, et al. Inferring tumor progression from genomic heterogeneity. Genome Res. 2010;20:68–80. doi: 10.1101/gr.099622.109. [DOI] [PMC free article] [PubMed] [Google Scholar]
  47. Letouze E, Allory Y, Bollet MA, Radvanyi F, Guyon F. Analysis of the copy number profiles of several tumor samples from the same patient reveals the successive steps in tumorigenesis. Genome Biol. 2010;11:R76. doi: 10.1186/gb-2010-11-7-r76. [DOI] [PMC free article] [PubMed] [Google Scholar]
  48. Iafrate AJ, Feuk L, Rivera MN, Listewnik ML, Donahoe PK, Qi Y, et al. Detection of large-scale variation in the human genome. Nat Genet. 2004;36:949–951. doi: 10.1038/ng1416. [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Supplementary Information
Click here for additional data file. (1.1MB, pdf)

Articles from Leukemia are provided here courtesy of Nature Publishing Group

RESOURCES